Belgium
Augustine Therapeutics, founded in 2019, is making significant strides in the biopharma, biotechnology, and pharmaceutical industries. With a mission encapsulated in the slogan "Innovative Therapies for Neuromuscular and Neurodegenerative Disorders," the company is dedicated to developing therapies for conditions such as Charcot-Marie-Tooth disease (CMT), peripheral neuropathies, and neurodegenerative diseases.
The venture is backed by research from VIB and KU Leuven and boasts financial and strategic support from notable investors, including Asabys Partners, Eli Lilly and Company, and V-Bio Ventures. Among its recent financial milestones, Augustine Therapeutics secured a substantial €60.00M Series A investment on 01 March 2025, with contributors such as Novo Holdings, Newton BioCapital, and Jeito Capital.
Headquartered in Belgium, Augustine Therapeutics is well-positioned as a trailblazer in its field, demonstrating both a solid scientific foundation and financial robustness, appealing to the discerning investor.
